Calcium antagonist effectiveness and tolerability in hypertensive men and women
Abstract
Aim. To compare effectiveness and tolerability of first- and second-generation dihydropyridine calcium antagonists (CA): instant-release nifedipine (Nifedipine IR) and slow-release nifedipine (Nifecard XL), in patients with arterial hypertension (AH). Material and methods. This 8-week randomized, open, comparative trail included 73 men and 74 women with Stage I-II AH; mean age was 53.4±12.9 and 55.3±9.3 years, AH duration - 13.8±9.3 and 16.3±9.7 years, respectively. All participants received either Nifecard XL (initial dose 30 mg/d, 1 tablet), or Nifedipine IR (30 mg/d, 3 tablets). Antihypertensive effect was assessed by office blood pressure (BP) measurement and 24-hour BP monitoring (BMP). Results. After 8 weeks of treatment, systolic and diastolic BP (SBP, DBP) reduced significantly in males and females, especially in Nifecard XL group. Daytime SBP variability also decreased. SBP variability tended to increase in females receiving Nifedipine IR. Women were more compliant to Nifecard XL therapy than to Nifedipine IR treatment: 99.8±7.9% vs 96.4±6.3%, respectively. Adverse effect rate was similar in males and females receiving Nifecard XL. Conclusion. High compliance, relatively low effective dose, low adverse effect rate, and better tolerability allow to recommend Nifecard XL for AH treatment in men and women.
About the Authors
A. E. Bragina
I.M. Sechenov Moscow Medical Academy. Moscow
Russian Federation
Russian Federation
I. G. Fomina
I.M. Sechenov Moscow Medical Academy. Moscow
Russian Federation
Russian Federation
V. V. Matveev
I.M. Sechenov Moscow Medical Academy. Moscow
Russian Federation
Russian Federation
References
1. US Bureau of the Census Projections of the population of the United States: 1997 to 2050. Current Population Reports Government Printing Office. Washington DC; 25-704.
2. Lowenstein SR, Schreir RW. Social and political aspects of aging. In: Schreir RW, ed. Clinical Internal Medicine in the Aged. WB Saunders Co., Philadelphia 1982; 1-25.
3. Miles TP, Bernard MA. Morbidity, disability, and health status of black. American elderly: a new look at the oldest-old. J Am Geriart Soc 1992; 40: 1047.
4. Medical Research Council Working Group Party. MRC trial of treatment of mild hypertension: principal results. Br Med J 1985; 291: 2572-7.
5. Neaton JP, Grimm RH, Prineas RJ, et al. Treatment of mild hypertension study. Final results. JAMA 1993; 270: 713-24.
6. Prevention of stroke by antihypertensive drug treatment in older persons with isolated “systolic” hypertension: Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255-64.
7. Wassertheil-Smoller S, Anderson G, Psaty BM, et al. Hypertension and its treatment in postmenopausal women: baseline data from the Women’s Health Initiative. Hypertension 2000; 36(5): 780-9.
8. Al-Azzawi F. The menopause and its treatment in perspective. Postgrad Med 2001; 77(907): 292-304.
9. Клименченко Н.И. Влияние заместительной гормональной терапии на сердечно-сосудистую систему у женщин с климактерическим синдромом в постменопаузе: Автореф дисс канд мед наук. Москва 1996.
10. Вебер В.Р. Возрастные и биоритмологические особенности гипертонической болезни у мужчин и женщин. Автореф дисс докт мед наук. Новосибирск 1992; 36 с.
11. Маличенко С.Б., Овчинникова С.Г. Постменопаузальный метаболический синдром: новые возможности терапии. Фарматека 2004; 6(84): 73-8.
12. Кириченко А.А. Лечение гипертонической болезни у женщин в постменопаузе. Практик врач 2003; 1: 5-8.
13. Calhoun DA, Oparil S. Gender and blood pressure. In: Hypertension primer. Izzo J.L., Black H.R. (eds). Dallas 2003; 253-7.
14. Wood MJ; Cox Jl- HRT to prevent cardiovascular disease. What studies show, how to advise patients. Postgrad med 2000; 108(З): 59-72.
15. Ильина Э.М. Генез вегетативно-сосудистых расстройств у больных с климактерическим синдромом. Автореф дисс канд мед наук. Москва 1986.
16. Ткаченко Н.М. Состояние вегетативной нервной системы при физиологическом течении климактерического периода и климактерическом синдроме. Москва 1988; 65-157.
17. Назаренко Н.В., Туева Р.С. Особенности артериальной гипертензии и обмен катехоламинов у больных патологическим климаксом. Пермь: Пермский мед институт. Сб науч тр 1983; 140: 43-5.
18. Lindqvist M, Kahan T, Melcher A, Hjemdahl P. Acute and chronic calcium antagonists treatment elevates sympathetic activity in primary hypertension. Hypertension 1994; 24: 287-96.
19. Van der Lee R, Kam KL, Pfaffendorf M, Van Zwieten PA. Differential time course of the vasodilatation action of various calcium antagonists. Fundam Clin Pharmacol 1998; 12: 607-12.
20. Brown MJ, Palmer C, Castaigne, et al. Morbidity and mortality in patients randomized to double-blind treatment with longacting calcium cannel blockers or diuretic in the International Nifedipine GITS Study: Intervention as a Goal in Hypertensive Treatment (INSIGHT). Lancet 2000; 356: 366-72.
21. Mancia G, Ferrari A, Gregorni L, et al. Blood pressure variabilities in normotensive and hypertensive human beings. Circ Res 1983; 53: 96-104.
22. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003; 28: 1427-34.
Review
For citations:
Bragina A.E., Fomina I.G., Matveev V.V. Calcium antagonist effectiveness and tolerability in hypertensive men and women. Cardiovascular Therapy and Prevention. 2006;5(4):46-51. (In Russ.)
Views:
499
Email this article 
